Search

everythinglearnresearchcommunity

for

Search:↓

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

Kx-826 at 0.5% shows limited effectiveness for hair loss, while 1% is more promising but expensive. RU58841 is considered a more feasible option until 1% kx-826 becomes affordable.

Hair loss treatments discussed include Minoxidil, Finasteride, microneedling, red light therapy, and biotin pills. The most proven treatments are Minoxidil, Finasteride, and microneedling, while other methods are considered less effective or satirical.

BackToTheFutehair's 3.5 month progress update on their hair loss treatment regimen of finasteride, minoxidil, and microneedling which has led to a significant improvement in thickness and life to the hair. Others have provided encouragement and advice for future treatments.

A user on finasteride for hair loss is considering topical dutasteride to further reduce scalp DHT and is using various other topicals as substitutes for minoxidil due to concerns about the safety of their cats and potential heart side effects from oral minoxidil. They are exploring whether a once-weekly application of topical dutasteride would be effective.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user experienced hair shedding after 1 year and 7 months on finasteride, possibly due to creatine use or a natural shedding phase. Despite concerns, they believe the shedding is temporary and expect hair to regrow thicker.

A 22-year-old is using 1mg finasteride daily for hair loss, noting some scalp thickening but still experiencing visible thinning. They are considering oral minoxidil due to concerns about topical application with cats at home, and others in the conversation share positive experiences with oral minoxidil, reporting no side effects and significant hair regrowth.

User shared 126-day progress using Fin/Min/Niz/Microneedling for hair loss. Others discussed microneedling depth, results timeline, frontal coverage, and switching to Dutasteride.

The conversation discusses the experience of hair shedding after starting sublingual oral Minoxidil, with the user questioning whether to continue the treatment. Responses suggest persisting with the treatment as shedding might lead to positive results.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

A user experienced increased hair shedding after 3.5 years on finasteride and is considering switching to dutasteride. Another user advised using both finasteride and dutasteride for 3 months before dropping finasteride.

The user is hesitant to start Fin and Min due to their long-term commitment and is currently on a 2-month supplement course. Another user suggests that the supplements are ineffective and recommends using Fin and Min for androgenetic alopecia.

The post discusses using Mucuna pruriens, essential oils, and dermarolling for hair loss treatment. The user also mentions pausing testosterone-boosting herbs due to side effects like acne and hair loss.

User discusses Pyrilutamide's effectiveness for hair loss, needing more time for results. Others suggest waiting 6-12 months and ask about side effects.

The user experienced significant hair regrowth using a combination of minoxidil, alfatradiol, pyrilutamide, and nizoral, despite previous intolerance to finasteride. They emphasize the importance of consistency in treatment and are optimistic about the results, noting no side effects so far.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.